PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes
Molecular Omics · 10.05.2023 · 19 (7) · 560-573
DOI: 10.1039/d3mo00033h ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, online erschienen am 10.05.2023. Verfasst von Yingkun Sheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Component-based Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medici…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Antineoplastic Agents, Atherosclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Tianjin Science and Technology Program, Tianjin Research Innovation Project for Postgraduate Students.
Abstract (Originalsprache)
Background
The DNA damage repair enzyme, poly(ADP-ribose) polymerase 1 (PARP1), is crucial for lipid and glucose metabolism. However, no evidence has been presented on the relationship between liver lipid accumulation and the PARP1 inhibitor, 3-aminobenzamide (3-AB), in atherosclerosis.
Methods
ApoE−/− mice were used to explore the effect of 3-AB on atherosclerotic liver lipid accumulation, and the experiment of Sprague Dawley (SD) rats was designed to determine if the lowering of liver lipid levels by 3-AB was linked to gut bacteria. The levels of bile acid metabolism-related targets were assessed by ELISA, western blotting, and RT-qPCR. The relative abundances of gut microbes and biomarkers were determined using 16S rRNA sequencing analysis. Bile acid levels in the liver and ileum were examined by ultra-performance liquid chromatography-tandem mass spectrometry. The relationship between gut microbes and bile acids was assessed by Spearman's correlation analysis.
Results
3-AB significantly reduced the formation of aortic plaques in apoE−/− mice, according to gross oil red staining. H & E and Oil Red O staining revealed that 3-AB significantly reduced the hepatic lipid droplet area in ApoE−/− mice and SD rats. Compared with the atherosclerosis (ATH) group, 3-AB dramatically decreased the levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) in the serum of SD rats and apoE−/− mice, and the levels of TC, TG, and LDL-C in the serum and liver of apoE−/− mice. Furthermore, in apoE−/− mice and SD rats, 3-AB increased the mRNA and protein levels of farnesoid X receptor (FXR) and bile salt export pump (BSEP) in the liver, while inhibiting the mRNA and protein levels of FXR and fibroblast growth factor 15 (FGF15) in the ileum, respectively. 3-AB clearly inhibited the mRNA and protein levels of PARP1 in the liver and ileum of apoE−/− mice and rats. Following treatment with 3-AB, the levels of conjugated bile acids decreased in the liver of apoE−/− mice and increased in the ileum of SD rats, according to targeted metabolomic analysis. Microbiome sequencing analysis revealed that 3-AB reduced the relative abundance of Lactobacillus, Bifidobacterium, Listeria, Clostridium, Bacillus, and Staphylococcus in the feces of apoE−/− mice, and the relative abundance of Blautia, Clostridium, and Listeria in the feces of SD rats, eventually decreasing the total abundance of 10 bile salt hydrolase-associated gut microbes. According to the correlation analysis, 3-AB regulates bile acid metabolism, which is primarily related to Bifidobacterium.
Conclusion
3-AB alleviated atherosclerosis by modulating the bile acid metabolism and bile salt hydrolase-related gut microbes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Component-based Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Ti…
- Department of Pharmacy, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China.
ORCID-Profile: Zhirong Zhou, Ruijiao Du, Miaomiao Jiang
Förderung
- Tianjin Science and Technology Program
- Tianjin Research Innovation Project for Postgraduate Students
Zitieren
APA
Sheng, Y., Meng, G., Zhou, Z., Du, R., Wang, Y., & Jiang, M. (2023). PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes. Molecular Omics, 19(7), 560-573. https://doi.org/10.1039/d3mo00033h
Vancouver
Sheng Y, Meng G, Zhou Z, Du R, Wang Y, Jiang M. PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes. Molecular Omics. 2023;19(7):560-573. doi:10.1039/d3mo00033h
BibTeX
@article{Sheng2023,
author = {Sheng, Yingkun and Meng, Guibing and Zhou, Zhirong and Du, Ruijiao and Wang, Yuefei and Jiang, Miaomiao},
title = {PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes},
journal = {Molecular Omics},
year = {2023},
volume = {19},
number = {7},
pages = {560--573},
doi = {10.1039/d3mo00033h}
}
EUVIMED